The P-II trial assesses riliprubart for the treatment of CIDP in patients who are SoC-treated (cohort 1), SoC-refractory (cohort 2) & SoC-naïve (cohort 3) for 24wks. (part A) with an optional treatment expansion for 52wks. (part B)
Study showed improved or stable responses in 87% SOC-treated (52% had greater improvement vs SoC), 89% SOC-refractory (50% had improvement) & 92% SOC-naïve patients at 24wks. with 72%, 89% & 71%, respectively, remaining on response for another 1yr.
Sanofi has begun 2 P-III trials to find the safety & efficacy of riliprubart with MOBILIZE study for SoC refractory CIDP patients & VITALIZE study for CIDP adults on maintenance therapy with immunoglobulin (IV)
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi Highlights the P-III (IMROZ) Study Data of Sarclisa for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
